Hector Franco, PhDUniversity of North Carolina, Chapel Hill2022 Lester and Bernice Smith Pilot Study Award Identifying Drivers of Therapeutic Resistance in Ovarian Cancer at Single-Cell Resolution Ovarian cancer is one of the deadliest cancers among women worldwide. Most women respond well to the standard treatment; however, up to 75% of these patients experience a recurrence […]
Read More
Sneha Saxena, PhDMassachusetts General Hospital2022 James A. Harting Scientific Scholar Award Targeting ovarian cancer by exploiting a novel type of replication stress induced by unprocessed uracil in DNA Despite decades of work to develop new treatments, the five-year survival of patients with advanced ovarian cancer is between 10-30 percent. Hence, there is a pressing need […]
Read More
Sarah Gitto, PhDUniversity of Pennsylania2022 Pape Family Scientific Scholar Award Transcriptomic and proteomic analysis of tumor-specific TILs to enhance immunotherapy in ovarian cancer Immunotherapies aim to enhance the immune system’s capability of eliminating disease within the body. Often, immunotherapy for cancer targets a type of immune cell called T cells to activate their ability to […]
Read More
John Paul Shen, MDUniversity of California, San Diego Improving Outcomes in Ovarian Cancer: A Network Genomics Approach Technological advances now allow for sequencing of tumors from large patient cohorts. However, this knowledge of the cancer genome has not yet been translated into the clinical practice of oncology. Dr. Shen works in the Ideker lab which […]
Read More
Tomer Shlomi, PhDTechnion Institute (Israel) Targeting ovarian cancer via MTAP synthetic lethality Ovarian cancer cells are genetically unstable. A deletion of the gene MTAP, which is involved in methionine metabolism, is found in 3-15% of ovarian tumors. As a result, affected ovarian cancer cells have lost a functional enzyme for metabolizing old proteins which is […]
Read More
Gokul Das, PhD, MPhil, MSRoswell Park Cancer Institute Functional analysis of mutant p53-estrogen receptor beta signaling crosstalk in high-grade serous ovarian cancer High-grade serous ovarian cancer is strikingly similar to triple negative breast cancer as both can be particularly aggressive cancers and are likely to recur. Dr. Das has found that these two diseases are […]
Read More